Research and Clinical Trials

RTOG 0625: A Randomized Phase II Trial of Bevacizumab With Irinotecan or Bevacizumab With Temozolomide in Recurrent Glioblastoma
Brief Description  
This randomized phase II trial is studying the side effects and how well giving bevacizumab together with irinotecan or temozolomide works in treating patients with recurrent or refractory glioblastoma multiforme or gliosarcoma. This project is being conducted at the following locations: Carolinas Medical Center/Blumenthal Cancer Center, Carolinas Hematology-Oncology Associates, and Mecklenburg Medical Group.
Who may be Eligible  

Patients must meet the following inclusion criteria to be eligible to enter the study:
  • Histologically confirmed intracranial glioblastoma multiforme (GBM) or gliosarcoma
  • Recurrent or refractory disease.
  • Age > 18
  • Must have received prior temozolomide
  • Pathologic or imaging confirmation of tumor progression or regrowth required
  • No bleeding within the tumor on MRI scan
  • Not pregnant or nursing
  • No prior history of cancer, except non-melanoma skin cancer or carcinoma in situ of the cervix
  • Unless the patient has been disease free and off therapy for that disease for = 3 years
IRB Number  
Principal Investigator  
Brick, Wendy

For More Information, Contact  Donna  , Couture-Johnson
Phone:  (704) 355-1677  Fax:  (704) 355-1188  
Address:Blumenthal Cancer Center 1025 Morehead Medical Drive Suite 600 Charlotte, NC